Endpoints News 生物医药· Anna Brown·· 10 天前AI 评分35
Neurosterix 筹集 1.05 亿美元用于精神分裂症药物开发
Neurosterix pulls in $105M for schizophrenia drug, taps Cobenfy vets
AI 导读
Neurosterix 获得 1.05 亿美元 B 轮融资,旨在推进其用于治疗精神分裂症的候选药物。公司重组了 Cobenfy 的核心团队。
正文
Neurosterix, which is reuniting some key figures behind Cobenfy, has corralled $105 million in a Series B to fund its lead schizophrenia candidate that hits …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
来源:Endpoints News 生物医药 · endpoints.news